(PRSS) Announces Definitive Agreement to Sell Art Business to Circle Graphics, Inc.

Divestiture Accelerates Strategic Goals of Streamlining the Business and Focusing on CafePress.com Company Announces Preliminary Fourth Quarter Results and Date of Earnings Call

CafePress Inc. (NASDAQ:PRSS), the on-demand printing leader, today announced that it has reached a definitive agreement to divest its Art business. The divesture is a component of the Company’s strategy to streamline operations, optimize its product offerings and focus on growing its core business, CafePress.com.

Under terms of the agreement, CafePress would sell its Art business to privately held Circle Graphics, Inc., for approximately $31.5 million in cash. Although no assurances as to timing can be made, the transaction is expected to close during the first quarter of 2015, and is subject to certain adjustments and closing conditions. The Art business represented approximately 20 percent of CafePress’s total revenues in 2014.

“We believe this transaction will advance the important goals of our strategic evaluation process, namely simplifying our business, significantly strengthening our balance sheet and aligning our expense run-rate with our revenues. This move is intended to accelerate our ability to concentrate on optimizing our business and increasing stockholder value,” said CEO Fred Durham.

Preliminary Fourth Quarter Results

CafePress also announced preliminary, unaudited fourth quarter revenue results. For the fourth quarter of 2014 CafePress expects to report revenues in the range of $82 – $84 million and expects its earnings per share to be substantially below analyst consensus estimates. CafePress ended the year with approximately $30 million in cash as of December 31, 2014.

Fourth Quarter and Fiscal Year 2014 Conference Call Information

CafePress Inc. announced it will report its fourth quarter and fiscal year 2014 financial results for the period ended December 31, 2014 following the close of market on Wednesday, February 25, 2015. On that day, management will hold a conference call and webcast at 5:00 p.m. ET (2:00 p.m. PT) to review and discuss the Company’s results. To participate on the live call, analysts and investors should dial 1-888-438-5519 at least ten minutes prior to the call. CafePress will also offer a live and archived webcast of the conference call, accessible from the “Investors” section of the Company’s web site at http://investor.cafepress.com/.

Notice Regarding Forward Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements as to the likelihood, timing, proceeds and impact of the divestiture transaction on the Company’s goals, focus, and financial performance, including statements regarding the Company’s belief that the divestiture transactions will advance the goals of its strategic evaluation process, including simplifying its business, significantly strengthening its balance sheet and aligning its expense run-rate with revenues, statements that the divestiture transaction is intended to accelerate the Company’s ability to concentrate on optimizing its business and increasing stockholder values, statements about the Company’s expectations for fourth quarter financial results, including GAAP and non-GAAP revenue, and statements about the Company’s strategic and investment plans, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including, but not limited to, risks relating to the Company’s ability to successfully close and divest its art business, the impact of the divestiture on the Company’s operations and financial performance, the Company’s ability to compete effectively, economic downturns, the impact of seasonality on the Company’s business. The estimates of fourth quarter revenue are preliminary and so subject to change. There can be no assurance that when the company completes its review of these results, its final determination of fourth quarter 2014 revenues and earnings will be different than the preliminary estimates described above. More information regarding these and other risks, uncertainties and factors is contained in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed with the SEC, and in other reports filed by the Company with the SEC from time to time. These forward-looking statements speak only as of the date hereof. CafePress disclaims any intention or obligation to update or revise any forward-looking statements.

About CafePress [PRSS]:

CafePress is passionate about helping individuals forge connections and celebrate their identities, interests and obsessions through unique products and content.

Our customers include people from all walks of life who are drawn to products that are emotional, inspirational and motivational. CafePress continues to enhance its assortment of designs, brands, images and base goods within its library of print-on-demand products. This expansion solidifies CafePress’ reputation as the ultimate resource for creating connections and bring-to-life creativity, opinions and passions. For more information, visit www.cafepress.com or connect with CafePress on Facebook, Twitter, Pinterest or YouTube.

(BLDP) Inks US$80M+ Deal With Volkswagen

– Transaction deepens strategic partnership

VANCOUVER, Canada and INGOLSTADT, Germany, Feb. 11, 2015  – Ballard Power Systems (NASDAQ: BLDP; TSX: BLD) today announced that the Company has entered into a Technology Solutions transaction with Volkswagen Group (Volkswagen AG, www.volkswagenag.com and Audi AG, www.audi.com) for an aggregate amount of approximately US$80 million for the transfer of certain automotive-related fuel cell intellectual property (IP) and a two-year extension of an engineering services contract.

Prof. Dr. Ulrich Hackenberg, Member of the Board of Management for Technical Development at AUDI AG and Coordinator of the Technical Development of all brands in the Volkswagen Group said, “Audi, VW and the Volkswagen Group are very pleased with the acquisition of a world-class automotive fuel cell patent portfolio. We believe that this portfolio, together with the combined fuel cell skills and expertise of our group and Ballard, will underpin our ability to play a leading role in fuel cell automotive development and commercialization.”

Randy MacEwen, Ballard President and CEO said, “This transaction extends and deepens our relationship with the Volkswagen Group, a leading global automotive manufacturer. The IP transfer surfaces significant value for Ballard. And, extension of the engineering services contract reflects a growing positive sentiment toward fuel cells within the automotive sector, along with the outstanding progress made to date in our work with Volkswagen Group on its fuel cell car programs.”

Transfer of Automotive-Related IP

Ballard will transfer the automotive-related portion of fuel cell IP assets previously acquired from United Technologies Corporation, in return for payments from Volkswagen Group totaling US$50 million, a majority of which is expected to be received at the closing of the transaction during the current quarter. The remainder is expected to be received in early 2016.

Ballard will retain a royalty-free license to utilize the IP transferred to Volkswagen Group in bus and non-automotive applications as well as for certain limited pre-commercial purposes in automotive applications.

Extension of Engineering Services Contract

The transaction also includes a 2-year extension, through March 2019, of the existing long-term engineering services agreement signed by Ballard and Volkswagen in 2013. This extension has an incremental value estimated at C$30-50 million (approximately US$24-40 million). Over the full 6-years, the contract has an estimated value of C$100-140 million (approximately US$80-112 million), and also includes a further optional 2-year extension.

Ballard’s ongoing engineering services contract with Volkswagen Group involves the design and manufacture of next-generation fuel cell stacks for use in the demonstration car program. Ballard engineers are leading critical areas of fuel cell product design – including the membrane electrode assembly (MEA), plate and stack components – along with certain testing and integration work.
Volkswagen Group’s commitment to, and progress in, fuel cell car development was underscored last November at the LA Auto Show, where fuel cell concept cars representing Volkswagen and Audi brand models were introduced: Golf SportWagen HyMotion, Passat HyMotion and Audi A7 Sportback h-tron quattro.

Mr. MacEwen added, “Ballard’s Technology Solutions group is helping customers accelerate fuel cell development through the application of our world-class, customized engineering services capability, along with access to our deep IP portfolio and related know-how. This transaction with Volkswagen marks a milestone in the growth and delivery of Ballard Technology Solutions.”

Ballard will provide further information regarding this transaction during the Company’s upcoming “2014 Results & 2015 Outlook” conference call, scheduled for 1:00 p.m. EST (10:00 a.m. PST) on Thursday, February 26, 2015.

About Ballard Power Systems

Ballard Power Systems (NASDAQ: BLDP; TSX: BLD) provides clean energy products that reduce customer costs and risks, and helps customers solve difficult technical and business challenges in their fuel cell programs. To learn more about Ballard, please visit www.ballard.com.

This release contains forward-looking statements concerning anticipated market growth drivers, product attributes and corresponding value propositions for our customers. These forward-looking statements reflect Ballard’s current expectations as contemplated under section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any such forward-looking statements are based on Ballard’s assumptions relating to its financial forecasts and expectations regarding its product development efforts, manufacturing capacity, and market demand.

These statements involve risks and uncertainties that may cause Ballard’s actual results to be materially different, including general economic and regulatory changes, detrimental reliance on third parties, successfully achieving our business plans and achieving and sustaining profitability. For a detailed discussion of these and other risk factors that could affect Ballard’s future performance, please refer to Ballard’s most recent Annual Information Form. Readers should not place undue reliance on Ballard’s forward-looking statements and Ballard assumes no obligation to update or release any revisions to these forward looking statements, other than as required under applicable legislation.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities.  The Ballard Common Shares have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

(AST) Completes Public Offering and Private Placement of Common Stock

MENLO PARK, Calif., Feb. 10, 2015  — Asterias Biotherapeutics, Inc. (NYSE MKT: AST) (the “Company”), a leading biotechnology company in the emerging field of regenerative medicine, announced today that it has completed the previously announced underwritten public offering and concurrent private placement of its common stock.

The Company raised $5.5 million in aggregate gross proceeds from the public offering and the private placement, which it intends to use for the continued development of product candidates through clinical trials and for working capital and general corporate purposes.

“This investment by new and existing investors, as well as by management, demonstrates the continued confidence in our strategic direction and the progress achieved with respect to our two key clinical development programs that have the potential to address significant unmet medical needs using our pluripotent stem cell technology platform,” stated Pedro Lichtinger, President and CEO of Asterias. “Of our two lead product candidates, AST-OPC1 for the treatment of complete cervical spinal cord injury has been cleared for a Phase 1/2a clinical trial and AST-VAC2 is expected to enter a Phase 1 clinical trial. Our strengthened cash position, combined with the non-dilutive funding that we secured last year from partnerships with leading scientific institutions, provides resources and flexibility required to execute our strategic plan in order to further advance these two products through meaningful clinical milestones.”

MLV & Co. LLC served as Sole Book-Running Manager for the public offering.  The common stock sold in the public offering was offered by the Company pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission.

About Asterias Biotherapeutics

Asterias’ core technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. Asterias plans to develop therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields having major unmet needs and without adequate therapies available. Asterias initial focus is on two clinical stage programs including oligodendrocyte progenitor cells (AST-OPC1) for spinal cord injuries and antigen-presenting allogeneic dendritic cells (AST-VAC2) for lung cancer.

Asterias is a majority-owned subsidiary of BioTime, Inc., (NYSE MKT: BTX), a biotechnology company engaged in research and product development in the field of regenerative medicine.

FORWARD-LOOKING STATEMENTS

Certain statements contained herein are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Asterias, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of Asterias, particularly those mentioned in the cautionary statements found in Asterias’ filings with the Securities and Exchange Commission. Asterias disclaims any intent or obligation to update these forward-looking statements

(CLIR) Jeffrey L. Ott Joins ClearSign Board of Directors

SEATTLE, Feb. 10, 2015  — ClearSign Combustion Corporation (NASDAQ: CLIR), an emerging leader in combustion and emissions control technology for industrial, commercial and utility markets, today announced the appointment of Jeffrey L. Ott as an independent director of the Company, effective immediately.

Mr. Ott is the President and Chief Executive Officer of Quest Integrity Group, LLC, a platform company and a subsidiary of Team, Inc. (NYSE:TISI), with operations in advanced inspection and engineering assessment of critical energy infrastructure in the process, pipeline, production and power sectors.

“Jeff’s broad experience in the energy industry along with his depth of knowledge in investment banking will add a valuable perspective to our Board of Directors,” said Stephen E. Pirnat, ClearSign Chairman and CEO. “We appreciate his willingness to serve as a director and look forward to benefitting from his judgment and counsel.”

Mr. Ott has been involved with high-growth, industrial technology companies for over 25 years as an investor, director, advisor, and financier. His industry focus has included energy, automotive performance, software, process controls and NDT/E instrumentation. As a general partner at Gryphon Investors, he was responsible for managing the group’s middle market-focused technology investment interests. Mr. Ott previously managed the west coast private equity effort and technology investments as a general partner at Deutsche Bank Capital Partners and prior to that, led the global convertible and equity-linked capital markets effort for Bankers Trust. He began his career as an engineer in the Operations Analysis group at Rockwell International’s North American Aircraft. Mr. Ott holds a B.S. in Engineering Management and Operations Research from Southern Methodist University and an M.B.A. from the Amos Tuck School of Business at Dartmouth College.

About ClearSign Combustion Corporation

ClearSign Combustion Corporation designs and develops technologies that aim to improve key performance characteristics of combustion systems including energy efficiency, emissions control, fuel flexibility and overall cost effectiveness. Our patent-pending Duplex™ and Electrodynamic Combustion Control™ platform technologies improve control of flame shape and heat transfer and optimize the complex chemical reactions that occur during combustion in order to minimize harmful emissions. For more information about the Company, please visit www.clearsign.com

Cautionary note on forward-looking statements

This communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding the completion, timing and size of the proposed public offering.  Such forward looking statements involve risks and uncertainties, including, without limitation, risks and uncertainties related to market conditions and the satisfaction of closing conditions related to the proposed public offering. Such statements involve known and unknown risks that relate to future events or future financial performance and the actual results could differ materially from those discussed in this communication. There can be no assurance that ClearSign will be able to complete the proposed public offering. Risks and uncertainties that may cause ClearSign’s actual results to differ materially from those discussed in this communication can be found in the “Risk Factors” section of ClearSign’s Form 10-K, Forms 10-Q and other filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and ClearSign assumes no responsibility to update or revise any forward-looking statements contained in this communication to reflect events, trends or circumstances after the date of this communication.

(XONE) North American Production Service Centers Now Certified for ISO 9001:2008

• ExOne’s Troy, Mich. and North Huntingdon, Pa. facilities join Auburn, Wash.; Houston, Texas; and Las Vegas, Nev. in full ISO 9001:2008 Certification
• All PSCs noted for quality management systems that meet ISO requirements

NORTH HUNTINGDON, Pa., Feb. 10, 2015 — The ExOne Company (Nasdaq:XONE), a global provider of three-dimensional printing machines and printed products to industrial customers, today announced that its production service centers (PSCs) in North Huntingdon, Pa. and Troy, Mich. have been certified to ISO 9001:2008 as Industrial Additive Manufacturers by DAS Certification. With the latest two facility certifications, all five of ExOne’s PSCs in North America now have ISO certification, joining ExOne’s other PSCs in Auburn, Wash., Houston, Texas, and Las Vegas, Nev. ISO 9001:2008 certification designates that the ExOne North Huntingdon and Troy facilities’ quality management systems conform to the specific requirements of the ISO (International Organization for Standardization).

The ISO 9001:2008 standard is based on eight quality management principles, including a strong customer focus, commitment of top management, a process approach and continuous improvement. Receiving ISO 9001:2008 certification helps ensure that ExOne’s customers receive consistently high quality products and services. To achieve the certification, ExOne had to demonstrate its consistent ability to provide products that meet customer and applicable statutory/regulatory requirements, while enhancing customer satisfaction through the effective application of the system. This includes processes for continuous improvement and the assurance of conformity to customer and statutory/regulatory requirements.

“Receiving ISO certification demonstrates that ExOne’s binder jetting 3D printing technology consistently meets our customers’ expectations and product quality standards for industrial usage,” said Tim Pierce, ExOne’s U.S. Chief Operating Officer. “By earning this certification at all of our North American facilities, ExOne customers recognize that they can achieve a high-level of service and quality regardless of their business region or printing application.”

ISO is the world’s largest developer of voluntary international standards. ISO 9001:2008 establishes the criteria for a quality management system and is implemented by more than one million companies and organizations in more than 170 countries.

For more information on ExOne and its binder jetting 3D printing technology, visit: www.exone.com.

About ExOne

ExOne is a global provider of 3D printing machines and printed products, materials and other services to industrial customers. ExOne’s business primarily consists of manufacturing and selling 3D printing machines and printing products to specification for its customers using its in-house 3D printing machines. ExOne offers pre-production collaboration and print products for customers through its eight PSCs, which are located in the United States, Germany, Italy and Japan. ExOne builds 3D printing machines at its facilities in the United States and Germany. ExOne also supplies the associated materials, including consumables and replacement parts, and other services, including training and technical support, necessary for purchasers of its machines to print products.

Safe Harbor Regarding Forward Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects,” “estimates,” “projects,” “typically,” “anticipates,” “believes,” “appears,” “could,” “plan,” and other similar words. Such statements include, but are not limited to, statements concerning future revenue and earnings, involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, which include our ability to qualify more materials in which we can print; the availability of skilled personnel; the impact of increased operating expenses and expenses relating to proposed acquisitions, investments and alliances; our strategy, including the expansion and growth of our operations; the impact of loss of key management; our plans regarding increased international operations in additional international locations; sufficiency of funds for required capital expenditures, working capital, and debt service; the adequacy of sources of liquidity; expectations regarding demand for our industrial products, operating revenues, operating and maintenance expenses, insurance expenses and deductibles, interest expenses, debt levels, and other matters with regard to outlook; demand for aerospace, automotive, heavy equipment, energy/oil/gas and other industrial products; the scope, nature or impact of acquisitions, alliances and strategic investments and our ability to integrate acquisitions and strategic investments; liabilities under laws and regulations protecting the environment; the impact of governmental laws and regulations; operating hazards, war, terrorism and cancellation or unavailability of insurance coverage; the effect of litigation and contingencies; the impact of disruption of our manufacturing facilities or PSCs; the adequacy of our protection of our intellectual property; material weaknesses in our internal control over financial reporting and other factors disclosed in the Company’s Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. Because they are forward-looking, these statements should be evaluated in light of important risk factors and uncertainties.

Should one or more of these risks or uncertainties materialize, or should any of ExOne’s underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. The Company disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this news release.

CONTACT: For more information, contact:

         Media:
         Justin Falce
         Burson-Marsteller
         (412) 394-6698
         justin.falce@bm.com

         Investors:
         Brian W. Smith
         ExOne, Chief Financial Officer
         (724) 765-1350
         brian.smith@exone.com

         Deborah K. Pawlowski/Karen L. Howard
         Kei Advisors LLC
         (716) 843-3908 / (716) 843-3942
         dpawlowski@keiadvisors.com /
         khoward@keiadvisors.com

(FSLR) & (AAPL) Strike Industry’s Largest Commercial Power Deal

First Solar, Inc. (Nasdaq: FSLR) today announced that Apple has committed $848 million for clean energy from First Solar’s California Flats Solar Project in Monterey County, Calif. Apple will receive electricity from 130 megawatts (MW)_AC of the solar project under a 25-year power purchase agreement (PPA), the largest agreement in the industry to provide clean energy to a commercial end user.

“Apple is leading the way in addressing climate change by showing how large companies can serve their operations with 100 percent clean, renewable energy,” said Joe Kishkill, Chief Commercial Officer for First Solar. “Apple’s commitment was instrumental in making this project possible and will significantly increase the supply of solar power in California. Over time, the renewable energy from California Flats will provide cost savings over alternative sources of energy as well as substantially lower environmental impact.”

The 2,900-acre California Flats Solar Project occupies 3 percent of a property owned by Hearst Corporation in Cholame, Calif. Construction is expected to begin in mid-2015, and to be completed by the end of 2016. The output of the remaining 150MW of the project will be sold to Pacific Gas & Electric under a separate long-term PPA, and the project is fully subscribed between the Apple and PG&E PPAs.

In January, the Monterey County Planning Commission unanimously approved the California Flats Solar Project, sending the project to the Monterey County Board of Supervisors, which will consider final approval of the project today.

Building on its proven record of developing, building and operating utility-scale solar power plants, First Solar has placed a strategic focus on directly providing large commercial and industrial customers with wholesale electricity through long-term agreements. This deal marks the first wholesale commercial and industrial PPA executed by First Solar.

About First Solar, Inc.

First Solar is a leading global provider of comprehensive photovoltaic (PV) solar systems which use its advanced module and system technology. The company’s integrated power plant solutions deliver an economically attractive alternative to fossil-fuel electricity generation today. From raw material sourcing through end-of-life module recycling, First Solar’s renewable energy systems protect and enhance the environment. For more information about First Solar, please visit www.firstsolar.com.

For First Solar Investors

This release contains forward-looking statements which are made pursuant to safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements, among other things, concerning: our business strategy, including anticipated trends and developments in and management plans for our business and the markets in which we operate; future financial results, operating results, revenues, gross margin, operating expenses, products, projected costs, warranties, solar module efficiency and balance of systems (“BoS”) cost reduction roadmaps, restructuring, product reliability and capital expenditures; our ability to continue to reduce the cost per watt of our solar modules; our ability to reduce the costs to construct photovoltaic (“PV”) solar power systems; research and development programs and our ability to improve the conversion efficiency of our solar modules; sales and marketing initiatives; and competition. These forward-looking statements are often characterized by the use of words such as “estimate,” “expect,” “anticipate,” “project,” “plan,” “intend,” “believe,” “forecast,” “foresee,” “likely,” “may,” “should,” “goal,” “target,” “might,” “will,” “could,” “predict,” “continue” and the negative or plural of these words and other comparable terminology. Forward-looking statements are only predictions based on our current expectations and our projections about future events. You should not place undue reliance on these forward-looking statements. We undertake no obligation to update any of these forward-looking statements for any reason. These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by these statements. These factors include, but are not limited to, the matters discussed in Item 1A: “Risk Factors,” of our Annual Report on Form 10-K for the year ended December 31, 2013, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other reports filed with the SEC.

(PFNX) & (HSP) Collaboration To Develop And Commercialize Proposed LUCENTIS® Biosimilar

SAN DIEGO and LAKE FOREST, Ill., Feb. 10, 2015  — Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, and Hospira, Inc., (NYSE: HSP), the world’s leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today announced that the companies have entered into an agreement to exclusively develop and commercialize for worldwide sales PF582, Pfenex’s biosimilar candidate to Genentech’s LUCENTIS^® (ranibizumab injection). LUCENTIS had estimated global sales of approximately $4 billion in 2014 and is part of the broader $6.7 billion intraocular anti-VEGF (vascular endothelial growth factor) therapeutic segment.

Under the terms of the collaboration, Pfenex will receive an upfront payment of $51 million once the collaboration receives antitrust approval, and, over the next five years and beyond, will be eligible to receive a combination of development and sales-based milestone payments up to an additional $291 million, and tiered double-digit royalty on net sales of the product.

Pfenex and Hospira will share the Phase 3 equivalence clinical trial costs, and Hospira will be responsible for manufacturing and commercializing the product worldwide. The collaboration will be governed by an Executive Steering Committee consisting of equal representation from Pfenex and Hospira. The agreement also allows for additional future product collaborations.

“We are extremely pleased to announce our collaboration with Hospira, a recognized world leader in biosimilars. This collaboration further validates the product development strength and capability of Pfenex as we continue to advance our pipeline of biosimilar candidates,” said Bertrand Liang, chief executive officer, Pfenex Inc.

Pfenex is currently conducting a Phase 1b/2a clinical trial where 24 patients have been randomized to receive monthly intraocular injections of PF582 or LUCENTIS for 3 doses and ongoing patient follow-up for 12 months. The clinical trial’s primary objective is to evaluate safety and tolerability of PF582, with secondary objectives including comparative pharmacokinetic (PK) and pharmacodynamic (PD) evaluations to help demonstrate biosimilarity to LUCENTIS.

“We are excited to be entering this collaboration with Pfenex for its biosimilar candidate to LUCENTIS, which we expect will expand Hospira’s biosimilars pipeline to include a new therapeutic area. Pfenex has established expertise in the development of biosimilars, leveraging its proprietary expression technology together with differentiated bioanalytical characterization capabilities,” said Sumant Ramachandra, M.D., Ph.D., senior vice president, chief scientific officer, Hospira. “We look forward to working closely with the Pfenex team to offer patients, physicians and healthcare systems a more affordable treatment option for retinal diseases.”

The agreement is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act.

About Pfenex Inc.
Pfenex Inc. is a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value and difficult to manufacture proteins. The company’s lead product candidate is PF582, a biosimilar candidate to LUCENTIS (ranibizumab), for the potential treatment of patients with retinal diseases. Pfenex has leveraged its Pfenex Expression Technology^® platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, generics and next generation biologics.

Pfenex has used, and intends to continue to use, its Investor Relations website (http://pfenex.investorroom.com), as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit (http://pfenex.investorroom.com).

About Hospira
Hospira, Inc. is the world’s leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill. Learn more at www.hospira.com .

Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally relate to future events or Pfenex’s or Hospira’s future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern either of Pfenex’s or Hospira’s expectations, strategy, plans or intentions. Forward-looking statements in this press release include, but are not limited to: in the case of Pfenex, statements regarding the future potential of PF582, including future plans to develop, manufacture and commercialize PF582 and the potential to receive future milestone and royalty payments; and in the case of Hospira, its expectations regarding regulatory approvals, clinical trials and the actions of competitors. The companies’ expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, challenges inherent in creating and developing compounds and product candidates and economic, competitive, governmental, regulatory, legal, supply and other factors.  Information on these and additional risks affecting Hospira’s business and operating results are more fully discussed in the section entitled “Risk Factors” in its most recently filed annual report on Form 10-K, as updated by any subsequently filed quarterly report on Form 10-Q. Information on these and additional risks affecting Pfenex’s business and operating results are more fully discussed in the section entitled “Risk Factors” in its most recently filed quarterly report on Form 10-Q for the quarter ended September 30, 2014 and Pfenex’s subsequent periodic reports, including Pfenex’s Form 10-K for the year ended December 31, 2014, which is expected to be filed with the SEC in March of 2015. The forward-looking statements in this press release are based on information available as of the date hereof, and each of Pfenex and Hospira disclaims any obligation to update any forward-looking statements, except as required by law.

(ANTH) Completion of Interim Analysis, Phase 3 Blisibimod Trial for Systemic Lupus Erythematosus

— CHABLIS-SC1 study passes futility analysis and will continue to completion with an enhanced endpoint — Enrollment to be completed in 2015 with final data in Q3 2016 — Recent encouraging EMA feedback on BRIGHT-SC design to be incorporated prior to interim

HAYWARD, Calif., Feb. 10, 2015  — Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today announced the successful completion of an interim analysis of its Phase 3 trial (CHABLIS-SC1) of blisibimod in patients with Systemic Lupus Erythematosus and that the study should continue to completion as planned. An independent statistician conducted the interim futility analysis for the CHABLIS-SC1 study, evaluating the SRI-6 response at the 24 week time point. Enrollment in the trial is projected to conclude in mid-2015.

“While the results of the CHABLIS-SC1 interim futility analysis remain blinded to Anthera, we are very pleased that the study has passed this critical milestone and now look forward to finishing enrollment later this year,” said Dr. Colin S. Hislop, Anthera’s Chief Medical Officer.

Prior to the interim analysis and in response to recent input from the Company’s Scientific Advisory Board following the publication of clinical data from other Lupus studies with BAFF inhibitors, the Company modified the primary endpoint of CHABLIS-SC1 from SRI-8 response to SRI-6 response, which was previously a secondary endpoint of the study.  SRI-8 will remain a key secondary endpoint of the study. The Systemic Lupus Erythematosus Response Index (SRI) is an approved endpoint recognized by the FDA for previously approved therapeutics.

“Based on the wealth of new information regarding the treatment of SLE and BAFF inhibition, we are fortunate to have had the opportunity to adjust our trial design,” said Dr. Colin S. Hislop. “The SRI-6 endpoint has a history of consistency across multiple trials and represents the best possibility for success. Maintaining the SRI-8 endpoint as a key secondary endpoint can maximize our commercial opportunity for the severe patients we are enrolling in the CHABLIS-SC1 study.”

Anthera has also completed a Scientific Advice Process meeting with the European Medicines Agency (EMA) regarding the blisibimod development program for the treatment of IgA Nephropathy (IgAN).  Earlier this quarter the Company obtained written feedback regarding the acceptability of a single pivotal study as the initial basis for a conditional market authorization application (MAA) in the European Union utilizing proteinuria as the primary endpoint.  In addition, the EMA also provided recommendations to address treatment duration, durability of response and need for re-treatment in the BRIGHT-SC study.  Anthera and its Japanese development partner Zenyaku Koygo Co., Ltd. plan to incorporate them in a protocol amendment prior to the planned interim analysis for the BRIGHT-SC study which will be completed later this quarter.

“We are pleased by the feedback from the EMA on the IgAN development program, which supports our global approach in IgAN.  This comes at a time when we are actively expanding our recruitment efforts throughout the world,” said Dr. Colin S. Hislop.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including systemic lupus erythematosus, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis.

About Blisibimod

Anthera is developing blisibimod, a selective inhibitor of B-cell activating factor (BAFF), to explore its clinical utility in various autoimmune diseases including systemic lupus erythematosus (SLE) and IgA nephropathy. Blisibimod is a novel FC-fusion protein, or peptibody, and is distinct from an antibody. BAFF is a tumor necrosis family member and is critical to the development, maintenance and survival of B-cells. Abnormal elevations of B-cells and BAFF may lead to an overactive immune response, which can damage normal healthy tissues and organ systems. Multiple clinical studies with BAFF antagonists have reported the potential benefit of BAFF inhibitors in treating patients with lupus and IgAN.

About Sollpura (liprotamase)

Sollpura is a soluble, stable and non-porcine enzyme product intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI) due to cystic fibrosis, and potentially other diseases. EPI is characterized by low absorption of fat and other nutrients due to a reduction in digestive enzymes produced by the pancreas.  Unlike other enzyme products for EPI, Sollpura’s chemical characteristics make it ideal for formulation as either a capsule or sachet product for co-administration with a variety of food products.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as “estimate,” “intend,” “anticipate,” “believe,” “plan,” “goal,” “expect,” “project,” or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera’s expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera’s public filings with the SEC, including Anthera’s Annual Report on Form 10-K for the year ended December 31, 2013 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2014.  Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., dlutz@anthera.com or 510.856.5598.

(IPWR) Names Ideal Power as Aegis Partner and Orders More Than 1 MW of Converters

(CBMG) Acquiring Chinese PLA General Hospital’s CAR-T Immuno-Oncology Tech

PALO ALTO, Calif., Feb. 9, 2015  — Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (“CBMG” or the “Company”), a biomedicine company engaged in the development of cellular therapies for degenerative and cancerous diseases, today announced its acquisition of Chinese PLA General Hospital’s (“PLAGH”, Beijing, also known as “301 Hospital”) Chimeric Antigen Receptor T cell (CAR-T) therapy, its recombinant expression vector CD19, CD20, CD30 and Human Epidermal Growth Factor Receptor’s (EGFR or HER1) Immuno-Oncology patents (all pending), and Phase I/II clinical data of the aforementioned therapies and manufacturing knowledge.

“This CAR-T cell technology acquisition further accelerates CBMG’s growth in the Immuno-Oncology segment. We look forward to working with PLAGH as a long-term partner as we evaluate paths to commercialization,” commented Dr. William (Wei) Cao, Chief Executive Officer of Cellular Biomedicine Group.

CAR-T cell therapy involves engineering cancer patients’ own immune cells to recognize and attack their tumors. Wei Dong Han, MD, PhD, head of PLAGH’s Biotherapy Department, is a renowned key opinion leader in the cancer immunotherapy field. Professor Han’s team has conducted several preliminary clinical studies of various CAR-T constructs targeting CD19-positive acute lymphoblastic leukemia, CD20-positive lymphoma, CD30-positive Hodgkin’s lymphoma and EGFR-HER1-positive advanced lung cancer. PLAGH is a top-ranking medical center in China, holding to the highest academic standards. The hospital consists of 125 clinical, medical and technological departments and 4,000 patient beds, with annual volumes of approximately 4 million patients and more than 65,000 surgeries.

Prior to acquiring PLAGH’s technology, the Company has made progress with recent acquisitions of Agreen Biotech Co. Ltd. and its T-Cell Memory technology (Tcm), T Cell Receptor clonality analysis technology, as well as another third generation CAR-T, anti-PD-1, CD19 and aAPC cancer immunotherapy technologies from Persongen Biotechnology Ltd. Together with PLAGH’s technology, CBMG’s state-of-the art infrastructure and clinical platform, along with these acquired technologies will enable improvement of cancer immune cell therapies and strategic combination therapies which will boost the Company’s Immuno-Oncology presence, and pave the way for future partnerships.

“We are very impressed by the quality of the work done by Dr. Han and his team at PLAGH, and are excited by the safe and efficacious profile of these novel T cell therapies for cancerous diseases, which we deem necessary to be a leader in this field while providing alluring prospective therapies for other cancers. This is the beginning of a long-term strategic partnership between CBMG and PLAGH. Together, we will expeditiously continue our quest in developing safer and more effective cancer immunotherapy programs with leading hospitals and other partners,” said Dr. William (Wei) Cao, Chief Executive Officer of Cellular Biomedicine Group.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com.

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as “may,” “will,” “expects,” “plans,” “intends,” “estimates,” “potential,” or “continue,” or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

CONTACT: Sarah Kelly
         Director of Corporate Communications, CBMG
         +1 650 566-5064
         sarah.kelly@cellbiomedgroup.com

         Vivian Chen
         Managing Director Investor Relations, Grayling
         +1 347 481-3711
         vivian.chen@grayling.com

(LFVN) Earns NSF Product Certification

LifeVantage Corporation Flagship Product, Protandim, Passes Globally Recognized Quality Certification Program

SALT LAKE CITY, Feb. 9, 2015  — LifeVantage Corporation (Nasdaq:LFVN), announced that its flagship product, Protandim, has earned certification from NSF International. Recognized by regulatory agencies at the local, state, federal and international level, NSF certification demonstrates that a product complies with all standard requirements for safety, quality, and performance. NSF conducts periodic facility audits and product testing to verify that the product continues to comply with the standard. LifeVantage is continuing to work with NSF International to complete certification for its international formula of Protandim, currently sold in Japan.

“We hold our suppliers, manufacturers, and employees to the highest quality standards,” said LifeVantage Chief Operating Officer, Robert M. Urban. “Earning NSF certification for Protandim is an honor, and helps assure customers worldwide that our product has been tested and certified to be of the highest quality by one of the most respected independent certification organizations in existence today.”

NSF International is dedicated to being the leading global provider of public health and safety-based risk management solutions while serving the interests of all stakeholders, namely the public, the business community and government agencies. The organization has received accreditation from the Occupational Safety and Health Administration (osha.gov), the Standards Council of Canada (SCC) (scc.ca), the American National Standards Institute (ANSI) (ansi.org) and the International Accreditation Service (iasonline.org). NSF laboratories worldwide are ISO/IEC 17025 accredited for testing and calibration.

About LifeVantage Corporation

LifeVantage Corporation (Nasdaq:LFVN), is a science based network marketing company that is dedicated to visionary science that looks to transform health, wellness and anti-aging internally and externally at the cellular level. The company is the maker of Protandim®, the Nrf2 Synergizer® patented dietary supplement, the TrueScience™ Anti-Aging Skin Care Regimen, Canine Health, and the AXIO™ energy product line.  LifeVantage was founded in 2003 and is headquartered in Salt Lake City, Utah.

CONTACT: Company Relations Contact:

         John Genna (801) 432-9172
         Vice President of Communications &
         Corporate Partnerships

         Investor Relations Contacts:
         Cindy England (801) 432-9036
         Director of Investor Relations
         -or-
         John Mills (646) 277-1254
         Partner, ICR INC

(MATR) Provides Update on Q4 Bookings and Book of Business

(ATOS) National Distribution Agreement With Thermo Fisher Scientific

(QTWW) Expects to Report Strong Sequential Q4 Product Revenue Growth

– Fourth quarter product sales expected to approximately double the third quarter level reported – Overall fourth quarter revenues expected between $12 million and $13 million – Sequential product growth driven by continued execution of storage systems strategy – Strong revenues complemented by solid order flow – product backlog anticipated to increase during fourth quarter by approximately $3 million to $17.8 million – Expect strong overall revenue growth in 2015

LAKE FOREST, Calif., Feb. 9, 2015  — Quantum Fuel Systems Technologies Worldwide, Inc. (NASDAQ: QTWW), a leader in natural gas storage systems, integration, and vehicle system technologies, today announced that it expects to report strong sequential revenue growth for its fourth quarter ending December 31, 2014.  Product sales for the fourth quarter are anticipated to approximately double relative to the level reported for the third quarter of 2014 due to strong customer demand for its natural gas fuel storage systems.  The Company also anticipates that it will report a robust product backlog of approximately $17.8 million at December 31, 2014 which is approximately $3 million higher than the $14.8 million the Company reported for the end of the third quarter.  The Company also expects to report a moderate improvement in its loss from continuing operations for the fourth quarter as compared to the third quarter which is driven primarily by increased product revenues and improved product margins. Finally, the Company believes that overall revenues will grow approximately 40% to 50% in 2015 based on existing and anticipated orders from its growing customer base and that related product margins will continue to improve during this period.

“We continue to experience traction in the industry as we effectively execute on our fuel storage systems strategy and we are excited to finish the year with anticipated strong sequential revenue growth and burgeoning order flow,” said Brian Olson, President and CEO of Quantum. “We began the process of fully implementing the systems strategy in the second half of 2014 and we believe we will recognize more revenues from our systems during this six-month period, basically right out of the gate, than we recognized on stand-alone tank sales during the first half of 2014.  We understand that the market was and remains concerned about the lost tank sales from a former key customer when we announced our direction into storage systems, but we have in a very short period demonstrated our ability to grow our customer base with our systems strategy,” concluded Mr. Olson.

In May 2014, Quantum announced its strategic direction to service the heavy duty OEM market segment, in addition to other market segments, with natural gas fuel storage systems. During 2014, Quantum brought to market its innovative, light-weight Q-Rail^LITE™ and Q-Cab^LITE™ CNG storage modules which are integrated CNG fuel systems for heavy-duty truck applications. Each storage module contains Quantum’s proprietary, ultra-light Q-Lite^® CNG storage cylinders, which further minimizes weight and increases fuel capacity.

The Company anticipates that it will finalize its results from operations for the three and twelve month periods ended December 31, 2014, subject to the review and completion of the audit of the twelve-month period ended December 31, 2014 by the Company’s auditors, and hold a conference call to discuss its 2014 financial results in early March.

About Quantum: Quantum Fuel Systems Technologies Worldwide, Inc. is a leader in the innovation, development and production of natural gas fuel storage systems and the integration of vehicle system technologies including engine and vehicle control systems and drivetrains. Quantum produces innovative, advanced, and lightweight compressed natural gas storage tanks and supplies these tanks, in addition to fully-integrated natural gas storage systems, to truck and automotive OEMs and aftermarket and OEM truck integrators. Quantum provides low emission and fast-to-market solutions to support the integration and production of natural gas fuel and storage systems, hybrid, fuel cell, and specialty vehicles, as well as modular, transportable hydrogen refueling stations. Quantum is headquartered in Lake Forest, California, and has operations and affiliations in the United States, Canada, and India.

Forward Looking Statements: This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding anticipated fourth quarter 2014 revenues, product sales, growth in product backlog, revenues from system sales relative to tank sales in 2014, improvement in net operating loss, improvement in product margins, anticipated revenues in 2015, and the timing for release of the 2014 financial results.  All statements included in this report, other than those that are historical, are forward looking statements and can generally be identified by words such as “may,” “could,” “will,” “should,” “assume,” “expect,” “anticipate,” “plan,” “intend,” “believe,” “predict,” “estimate,” “forecast,” “outlook,” “potential,” or “continue,” or the negative of these terms, and other comparable terminology. Various risks and other factors could cause actual results, and actual events that occur, to differ materially from those contemplated by the forward looking statements. Risk factors include the cancellation of orders, the acceptance of the Company’s products, and the other risk factors contained in our annual report on Form 10-K for the year ended December 31, 2013 and our interim reports on Form 10-Q for the first three quarters of 2014. Except as may be required by applicable law, the Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.

More information about the products and services of Quantum can be found at http://www.qtww.com/ or you may contact:

Quantum Investor Relations
Phone:  949-399-4555
Email:  ir@qtww.com

(PESI) to Present at The Brewer Group Innovations Conference

(TEAR) Announces Inducement Grant Under NASDAQ Rule 5635(c)(4)

SAN DIEGO, Feb. 6, 2015  — TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) (“TearLab” or the “Company”) today announced that on February 5, 2015, a majority of the independent members of the Company’s Board of Directors approved the grant of an option to purchase 100,000 shares of the Company’s common stock to Raymond Kong, the Company’s Vice President of Sales. The stock option has a ten-year term and a per share exercise price equal to the higher of (i) the closing price per share of the Company’s common stock as quoted on the Nasdaq Capital Market on February 5, 2015 or (ii) the prior five-day volume weighted average price of the Company’s common stock as quoted on the Nasdaq Capital Market at the close of business on February 5, 2015. The stock option has a vesting commencement date of February 5, 2015, and will vest in equal annual increments over a three year period, subject to Mr. Kong’s continued service with the Company through each applicable vesting date. In addition, the stock option will fully accelerate as to vesting in the event of a change of control prior to Mr. Kong’s termination of service. The stock option grant was made as an inducement that was material to Mr. Kong’s acceptance of employment with the Company and was granted as an employment inducement award pursuant to NASDAQ Listing Rule 5635(c)(4).

About TearLab Corporation

TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab® Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation’s common shares trade on the NASDAQ Capital Market under the symbol ‘TEAR’ and on the Toronto Stock Exchange under the symbol ‘TLB’.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about TearLab. Examples of forward-looking statements in this press release include statements regarding the future potential of the TearLab Osmolarity System and the related impact on our sales. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our annual and quarterly reports on Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.

CONTACT: Stephen Kilmer
         (647) 872-4849
         skilmer@tearlab.com

(CME) CFO John Pietrowicz to Present at Credit Suisse Forum February 11

CHICAGO, Feb. 6, 2015  — CME Group announced today that Chief Financial Officer John Pietrowicz will present at the 16^th Annual Credit Suisse Financial Services Forum, in Miami, Florida, on Wednesday, February 11, 2015, at 8:45 a.m. (Eastern Time).

The presentations will be broadcast live over the Internet and can be accessed via the exchange’s web site at http://investor.cmegroup.com.  Please allow extra time prior to the presentation to visit the site and download the streaming media software required to listen to the Internet broadcast.  An audio Webcast will be available for replay at the same address approximately 24 hours following the conclusion of the conference.

As the world’s leading and most diverse derivatives marketplace, CME Group (www.cmegroup.com) is where the world comes to manage risk. CME Group exchanges offer the widest range of global benchmark products across all major asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, metals, weather and real estate. CME Group brings buyers and sellers together through its CME Globex® electronic trading platform, its trading facilities in New York and Chicago, and through its London-based CME Europe derivatives exchange.  CME Group also operates one of the world’s leading central counterparty clearing providers through CME Clearing and CME Clearing Europe, which offer clearing and settlement services across asset classes for exchange-traded contracts and over-the-counter derivatives transactions.  These products and services ensure that businesses everywhere can substantially mitigate counterparty credit risk.

CME Group is a trademark of CME Group Inc. The Globe Logo, CME, Globex and Chicago Mercantile Exchange are trademarks of Chicago Mercantile Exchange Inc.  CBOT and the Chicago Board of Trade are trademarks of the Board of Trade of the City of Chicago, Inc.  NYMEX, New York Mercantile Exchange and ClearPort are registered trademarks of New York Mercantile Exchange, Inc.  COMEX is a trademark of Commodity Exchange, Inc.  All other trademarks are the property of their respective owners. Further information about CME Group (NASDAQ: CME) and its products can be found at www.cmegroup.com.

(UUUU) to Resume Development at High-Grade Canyon Uranium Mine

– Energy Fuels is preparing to resume development at its high-grade Canyon mine, located in northern Arizona – The Canyon mine contains 1.63 million pounds of U3O8 with an average grade of 0.98% – Ore production at the Pinenut mine continues to meet expectations in terms of total tonnage mined, ore grade and pounds of U3O8 recovered – Energy Fuels is clearly emerging as the dominant mining company focused on U.S. uranium production by adding ISR production through its pending acquisition of Uranerz Energy Corporation

Energy Fuels Inc.
Curtis Moore
Investor Relations
(303) 974-2140 or Toll free: 1-888-864-2125
investorinfo@energyfuels.com
www.energyfuels.com

(UEPS) Provides Further Update on SASSA Tender Process

JOHANNESBURG, SOUTH AFRICA–(February 06, 2015) – Net1 (NASDAQ: UEPS) (JSE: NT1) today provided a further update on the SASSA tender process.

As reported in the press release dated December 5, 2014, the Company filed further affidavits on January 20, 2015 and written submissions on January 27, 2015 with the South African Constitutional Court (“Court”), setting out the Company’s reasons and arguments for a Court order setting aside the Request For Proposal (“RFP”) and / or directing SASSA to issue a corrected RFP.

The Court issued further directions today by instructing SASSA to indicate to the Court by Tuesday, February 10, 2015 whether it intends to make further amendments to the RFP and, if so, to effect such changes by Friday, February 13, 2015. The Court indicated that further directions may be issued.

About Net1 (www.net1.com)
Net1 is a leading provider of alternative payment systems that leverage its Universal Electronic Payment System (“UEPS”), to facilitate biometrically secure, real-time electronic transaction processing to unbanked and under-banked populations of developing economies around the world in an online or offline environment. Net1’s UEPS/EMV solution is interoperable with global EMV standards that seamlessly permit access to all the UEPS functionality in a traditional EMV environment. In addition to payments, UEPS can be used for banking, healthcare management, payroll, remittances, voting and identification.

Net1 operates market-leading payment processors in South Africa and the Republic of Korea. In addition, Net1’s proprietary MVC technology offers secure mobile payments and banking services in developed and emerging countries.

Net1 has a primary listing on the NASDAQ and a secondary listing on the Johannesburg Stock Exchange.

Investor Relations Contact:
Dhruv Chopra
Head of Investor Relations
Phone: +1-917-767-6722
Email: dchopra@net1.com

(VBLT) Receives European Patent Issuance on Lecinoxoid Platform Technology

TEL AVIV, Israel, Feb. 6, 2015  — VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory diseases, today announced the issuance by the European Patent Office (EPO) of Patent No. 2348866, entitled “Oxidized Lipid Compounds and Uses Thereof” and covering the compound, pharmaceutical composition, and use of the Company’s second generation oral Lecinoxoids. VBL is currently applying its Lecinoxoid technology to anti-inflammatory indications, including psoriasis and ulcerative colitis. This patent provides intellectual property rights in validated European countries through 2029.

“This granted patent is an important addition to VBL’s Lecinoxoids intellectual property portfolio, which now includes more than 70 issued patents and pending patent applications worldwide,” said Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics. “VBL is committed to continuing to expand and strengthen our pipeline through multiple layers of intellectual property protection. We look forward to leveraging our second-generation molecules to additional immune-inflammatory indications in broad patient populations.”

VBL recently completed two Phase 2 studies evaluating the efficacy of lead Lecinoxoid compound, VB-201, for the treatment of psoriasis and ulcerative colitis. Top line results from both studies are expected in the first quarter of 2015.

About the Lecinoxoid Platform:

VBL’s proprietary Lecinoxoid platform technology comprises a family of orally administered small molecules designed to modulate the body’s inflammatory response. Lecinoxoids are compounds that are structurally and functionally similar to naturally occurring molecules, known as oxidized phospholipids, which possess immune modulating anti-inflammatory properties, modified to enhance stability and activity. The Lecinoxoid platform technology seeks to harness the ability of oxidized phospholipids to regulate and attenuate key immune-inflammatory signaling.

Lecinoxoids have the potential to act on two specific mechanisms: the inhibition of cellular signaling cascades associated with the innate immune system, known as toll-like receptor signaling, and the inhibition of the migration of monocytes toward chemoattractants present in areas of inflammation.

About VBL:

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory diseases. VBL Therapeutics’ clinical pipeline is based on two distinct, proprietary platform technologies—an oncology program and an anti-inflammatory program—that leverage the body’s natural physiologic and genetic regulatory elements. The Company’s lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer. VB-111 has received orphan drug designation in both the United States and Europe and was granted Fast Track designation by the FDA for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation. VBL Therapeutics expects to begin the pivotal Phase 3 trial for VB-111 in rGBM in the first half of 2015, under a special protocol assessment agreement granted by the FDA. VBL Therapeutics’ lead product candidate from its anti-inflammatory program, VB-201, is an oral small molecule which recently completed Phase 2 clinical trials for psoriasis and for ulcerative colitis, with top-line results expected in the first quarter of 2015.

Forward Looking Statements:

This press release contains forward-looking statements. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

CONTACT: Hannah Deresiewicz
         Stern Investor Relations, Inc.
         212-362-1200, hannahd@sternir.com

(LNCO) SEC Closes Inquiry of LINN Energy

HOUSTON, Feb. 5, 2015  — LINN Energy, LLC (Nasdaq:LINE) (“LINN”) and LinnCo, LLC (Nasdaq:LNCO) (“LinnCo” and together with LINN, the “Company”) announced today that the Fort Worth Regional Office of the Securities and Exchange Commission (“SEC”) has formally notified LINN that the SEC has closed its inquiry and does not intend to recommend any enforcement action against the Company.

“After a thorough and lengthy process, we are clearly very pleased with this excellent outcome,” said Mark E. Ellis, Chairman, President and Chief Executive Officer.

On July 1, 2013, LINN and LinnCo voluntarily disclosed the SEC’s informal inquiry. LINN and LinnCo cooperated fully with the SEC during its inquiry.

ABOUT LINN ENERGY

LINN Energy’s mission is to acquire, develop and maximize cash flow from a growing portfolio of long-life oil and natural gas assets. LINN Energy is a top-15 U.S. independent oil and natural gas development company, with approximately 7.8 Tcfe of proved reserves (pro forma for announced 2014 trades, acquisitions and divestitures) in producing U.S. basins as of December 31, 2013. More information about LINN Energy is available at www.linnenergy.com.

ABOUT LINNCO

LinnCo was created to enhance LINN Energy’s ability to raise additional equity capital to execute on its acquisition and growth strategy. LinnCo is a Delaware limited liability company that has elected to be taxed as a corporation for United States federal income tax purposes, and accordingly its shareholders will receive a Form 1099 in respect of any dividends paid by LinnCo. More information about LinnCo is available at www.linnco.com.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS

This press release includes “forward-looking statements.” All statements, other than statements of historical facts, included in this press release that address activities, events or developments that the company expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements include, but are not limited to forward-looking statements about acquisitions, divestitures and trades, timing and payment of distributions, and the expectations of plans, strategies, objectives and anticipated financial and operating results of the company, including the company’s drilling program, production, hedging activities, capital expenditure levels and other guidance included in this press release. These statements are based on certain assumptions made by the company based on management’s experience and perception of historical trends, current conditions, anticipated future developments and other factors believed to be appropriate. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the company, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. These include risks relating to the company’s financial performance and results, availability of sufficient cash flow to pay distributions and execute its business plan, prices and demand for oil, natural gas and natural gas liquids, the ability to replace reserves and efficiently develop current reserves and other important factors that could cause actual results to differ materially from those projected as described in the company’s reports filed with the Securities and Exchange Commission. See “Risk Factors” in the company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other public filings and press releases.

Any forward-looking statement speaks only as of the date on which such statement is made and the company undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACT: LINN ENERGY, LLC

         Investors & Media:

         Clay Jeansonne - Vice President - Investor Relations
         281-840-4193

         Sarah Nordin - Public Relations & Media
         713-904-6605

(GPRO) Channel Coming to Roku Streaming Platform

World’s Most Engaging User Generated Content Coming to Millions of Roku Customers

SAN MATEO, Calif., Feb. 5, 2015  — GoPro, Inc. (NASDAQ:GPRO), enabler of some of today’s most engaging content, today announced that it will launch a GoPro Channel on the Roku® streaming platform this spring. The custom-designed streaming channel will be a one-stop video destination that delivers on-demand GoPro content to millions of Roku customers.

With this agreement, Roku joins GoPro’s expanding roster of distribution partners including Xbox, LG and Virgin America.

“GoPro content is unique in that it emotionally resonates with a global audience,” said Adam Dornbusch, Head of Programming at GoPro. “The GoPro channel will make it simple for Roku customers to watch GoPro originally-produced and “best of” user-generated content on their televisions at home. We are excited to bring the world of GoPro to Roku customers as they are one of the most engaged customer bases when it comes to the amount of streaming content they view.”

When it launches on the Roku platform, the GoPro streaming channel will include:

• Featured playlists: Explore content from Deep Sea to Full Throttle
• Favorite videos: Readily access favorites and recently watched content
• Product Discovery: Learn which GoPro products were used to “get the shot”

“We’re incredibly excited to bring the action-packed videos created by the GoPro community to the Roku streaming platform,” said Ed Lee, vice president of content at Roku. “Roku delivers an experience that our customers truly love, and I know that they’re going to be captivated by the inspiring new content available to them with the launch of the GoPro channel this spring.”

To view content similar to what will air on the GoPro channel for the Roku platform, visit the GoPro Channel on YouTube. For more information on GoPro and its HERO line of cameras and accessories, visit GoPro.com.

About GoPro, Inc. (NASDAQ:GPRO)

GoPro, Inc. is transforming the way consumers capture, manage, share and enjoy meaningful life experiences. We do this by enabling people to capture engaging, immersive photo and video content of themselves participating in their favorite activities. Our customers include some of the world’s most active and passionate people. The quality and volume of their shared GoPro content, coupled with their enthusiasm for our brand, virally drives awareness and demand for our products.

What began as an idea to help athletes document themselves engaged in their sport has become a widely adopted solution for people to document themselves engaged in their interests, whatever they may be. From extreme to mainstream, professional to consumer, GoPro has enabled the world to capture and share its passions. And in doing so, the world, in turn, is helping GoPro become one of the most exciting and aspirational companies of our time.

For more information, visit www.gopro.com or connect with GoPro on YouTube, Twitter, Facebook, Pinterest or LinkedIn.

GOPRO® and HERO® are trademarks or registered trademarks of GoPro Inc. in the United States and other countries.

Roku is a registered trademark of Roku, Inc. in the U.S. and in other countries.

(APDN) Completes DNA Marking of 10,000 Bales of American Pima Cotton

SigNature(R) T DNA Campaign Supports Global Supply Chain Integrity for Cotton Textiles and Apparel Industries

(SMRT) Reports January Comparable Store Sales Increase of 6.6%

Fourth Quarter: Total Sales Increased 7.3% and Comparable Store Sales Increased 5.6%

JACKSONVILLE, Fla., Feb. 5, 2015  — Stein Mart, Inc. (Nasdaq:SMRT) today reported sales for the four weeks of January.

Geographically, the Midwest, Southeast and Gulf States had the strongest sales in January, while the West, Northeast and Florida had comparable store sales increases, but performed lower than the chain. For the fourth quarter, ladies’ apparel and home had the strongest sales, while accessories and men’s performed lower than the chain. The Company operated 270 stores at the end of January this year compared to 264 stores last year.

“Our fourth quarter 5.6 percent comparable store sales increase capped off a great second-half performance,” said Jay Stein, Chief Executive Officer. “Sales continued to build throughout the quarter, particularly as we did not have a repeat of last year’s severe weather events.”

Fourth Quarter and Fiscal 2014 Financial Results

Financial results for the fourth quarter and fiscal 2014 will be reported prior to the opening of the U.S. financial markets on Thursday, March 12, 2015. Management will also hold a conference call at 10:00 a.m. ET that morning to discuss those results. The call may be heard on the Company’s investor relations website at http://ir.steinmart.com. A replay of the conference call will be available on the website through March 31, 2015.

About Stein Mart

Stein Mart stores offer the fashion merchandise, service and presentation of a better department or specialty store, at prices competitive with off-price retail chains. With locations from California to Massachusetts, as well as steinmart.com, Stein Mart’s focused assortment of merchandise features current season, moderate to better fashion apparel for women and men, as well as accessories, shoes and home fashions. In 2014, Stein Mart was voted America’s “Best Department Store” by readers of USA TODAY.

SMRT-S

Additional information about Stein Mart, Inc. can be found at www.steinmart.com

CONTACT: Linda L. Tasseff
         Director, Investor Relations
         (904) 858-2639
         ltasseff@steinmart.com

(ROKA) Strengthens Management Team to Drive Growth

Appoints Mary Duseau as Chief Commercial Officer

WARREN, N.J., Feb. 5, 2015  — Roka Bioscience, Inc. (NASDAQ: ROKA), a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens, today announced that Mary Duseau has been named Senior Vice President and Chief Commercial Officer, reporting to Paul Thomas, President and Chief Executive Officer.

“I am pleased to announce the addition of Mary Duseau to our senior management team,” said Paul Thomas.  “Ms. Duseau has a distinguished background in commercial leadership and brings a level of experience and talent that we expect will help drive growth in our business and capitalize on opportunities for Roka to become a leader in the food safety testing market.”

Ms. Duseau brings more than 25 years of sales and marketing experience to her role as Chief Commercial Officer, most recently serving as Global Sales Director at Andor Technologies, a division of Oxford Instruments.  Prior to joining Andor Technologies, Ms. Duseau held various sales and management roles of increasing responsibility with Perkin Elmer from 2000 through 2012.

About Roka Bioscience

Roka Bioscience is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market. Our Atlas Detection Assays incorporate our advanced molecular technologies and are performed on our “sample-in, result-out” Atlas System that automates all aspects of molecular diagnostic testing on a single, integrated platform. The Atlas System and Detection Assays are designed to provide our customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies. For more information, visit http://rokabio.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended (the “Exchange Act”). These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. Any statements contained herein (including, without limitation, statements to the effect that we “believe”, “expect”, “anticipate”, “plan” and similar expressions) that are not statements of historical fact should be considered forward-looking statements. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward looking statements. There are a number of important factors that could cause actual results to differ materially from those indicated by such forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission.  Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this press release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.

Investor Contact:
Roka Bioscience, Inc.
ir@rokabio.com
855-ROKABIO (855-765-2246)
Source: Roka Bioscience

(EAC) Announces Organizational Restructuring

Erickson Incorporated (NASDAQ:EAC) announced today that it has initiated a comprehensive organizational restructuring that it anticipates will create significant new efficiencies and cost reductions, improve profitability, and enhance the Company’s overall competitive position. The Company will now be organized into the following four business segments:

• Government Aviation Services, led by Chris Bassett
• Oil & Gas Aviation Services, led by Santiago Crespo
• Commercial Aviation Services, led by Andy Mills
• Manufacturing & MRO, led by Kerry Jarandson

This significant restructuring marks the final stage of integration associated with the Evergreen Helicopters and Air Amazonia acquisitions. In connection with its business segment realignment, the Company is engaged in several operational initiatives that are focused on achieving substantial efficiency and accountability improvements across the business and are intended to enhance the Company’s overall profitability and cash flow position.

As part of the planned restructuring, Erickson will lay off approximately 150 employees. The layoffs will impact field, factory, and office locations, primarily in Oregon, but also at other U.S. locations.

”We value our team members deeply and have been fortunate to build an organization that has demonstrated exceptional quality and commitment,” said Udo Rieder, Erickson President and CEO. “This restructuring will create efficiency, reduce our costs, simplify lines of reporting and responsibility and enhance accountability. We believe we will be better able to address the challenges we have seen in our end markets, particularly in Defense and Oil & Gas, and reinforce our position as one of the world’s leading aviation services providers.”

About Erickson

Erickson is a leading global provider of aviation services specializing in oil and gas, government services, legacy aircraft MRO and manufacturing, and commercial services such as firefighting, HVAC, power line, specialty, construction, and timber harvesting. Erickson operates a fleet of 86 rotary-wing (light, medium, and heavy) and fixed-wing aircraft, including 20 heavy-lift S-64 Aircranes. Founded in 1971, Erickson is headquartered in Portland, Oregon, USA, and maintains operations in North America, South America, Europe, the Middle East, Africa, Asia Pacific, and Australia. For more information, please visit www.ericksonaviation.com.

This press release contains certain statements relating to future results (including, without limitation, “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict”), which are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on beliefs of Company management, as well as assumptions and estimates based on information currently available to the Company, and are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or those anticipated, including our inability to successfully execute on our business restructuring goals and also including certain other risks or uncertainties more fully described under the heading “Risk Factors” in our most recently filed Annual Report on Form 10-K as well as in the other reports we file with the SEC from time to time, which are available at the SEC’s web site located at http://www.sec.gov. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

(OHRP) Announces Proposed Public Offering of Common Stock

NEW YORK, Feb. 5, 2015  — Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that it intends to offer its common stock in an underwritten public offering. Ohr Pharmaceutical also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering to cover overallotments, if any. Ohr Pharmaceutical plans to use the net proceeds from the offering to fund clinical trials of OHR-102, the development of its pre-clinical pipeline and for general corporate purposes.

Cowen and Company, LLC is acting as the sole book running manager. LifeSci Capital, LLC is acting as co-manager of the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Ohr intends to offer and sell these securities pursuant to a shelf registration statement on Form S-3 (File No. 333-201368) filed with the Securities and Exchange Commission (“SEC”) on January 5, 2015 and declared effective on January 21, 2015.  A preliminary prospectus supplement and an accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may be obtained from Cowen and Company, LLC (c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, Phone: 631-274-2806, Fax: 631-254-7140). An electronic copy of the prospectus supplement and accompanying documents relating to the offering is available on the SEC website at www.sec.gov.

Before investing in the offering, you should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that Ohr has filed with the SEC that are incorporated by reference in the prospectus supplement and the accompanying prospectus, which provide more information about Ohr and the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company’s lead product, Squalamine, is currently being studied as an eye drop formulation (OR-102) in several company sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. The company also has a research agreement with Alcon on a sustained release program. Additional information on the company may be found at www.ohrpharmaceutical.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and Ohr Pharmaceutical undertakes no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA or Health Canada will approve final testing or marketing of any pharmaceutical product. Ohr’s most recent filings with the SEC discuss some of the important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements for any reason.

CONTACT: Investor Relations
         888-388-2327
         ir@ohrpharmaceutical.com

         LifeSci Advisors, LLC
         Michael Wood
         646-597-6983
         mwood@lifesciadvisors.com

(VSTA) Dr. Gerard Sanacora Joins VistaGen’s Clinical and Scientific Advisory Board

Yale Depression Expert to Advise on Late-Stage Development of Orally-Active AV-101 for Major Depressive Disorder

(SOFO) Cited as a Leader in Enterprise Video Platforms and Webcasting

Sonic Foundry, Inc. (NASDAQ: SOFO), the trusted global leader for video creation and management solutions, has been cited as a leader in The Forrester Wave™: Enterprise Video Platforms and Webcasting, Q1 2015.

Sonic Foundry was among the select companies that Forrester Research, Inc. invited to participate in its report. In this evaluation the company was cited as a leader in all three of the report’s categories —‘Webcasting,’ ‘Portals’ and the combined, comprehensive solution ‘Webcasting and Portals.’

The report, authored by Phillip Karcher, senior analyst, assesses 16 enterprise video platform and webcasting providers based on their current offerings, strategies and market presence.

“Video is becoming a more common channel that enterprises use to communicate — both internally with other employees and externally with customers and partners,” according to the report. “As enterprises look at applications for video across marketing, corporate communications, and training, selecting the right technology platform is an important decision … Selecting the right platform allows application development and delivery pros to maximize their opportunity to apply video communications to achieve organizational objectives and enhance customer and employee experiences.”

According to the report, Leaders have the following characteristics:

• A strong track record in the webcasting space, with interactive and customizable webcasting player experience, robust control platform to manage webcasts like staged events and tools to edit recordings
• Excellent portal features for video content management, uploading and encoding and workflow; supporting many options for video capture and good video editing tools
• Having the most complete offerings for organizations that want a multipurpose solution for webcasting and video portals

Sonic Foundry was also cited for:

• Webcasting player with in-video search and ability to show multiple camera feeds at once
• Portal and content management capabilities
• Desktop content creation tools
• Ability to ingest web conferencing recordings
• Cloud-based videoconferencing signal acquisition
• Restful API commitment

“We’re very pleased to be recognized by Forrester’s respected analysts. We believe that our status as a leader in this report solidly establishes Mediasite as a recognized solution for comprehensive video content management for the enterprise,” said Gary Weis, Sonic Foundry CEO. “We know what’s required for scalable, widespread adoption of content creation and management, having successfully helped more than 3,000 customers. We will continue to innovate best-in-class technologies for the knowledge workers of the future.”

Download the Forrester Wave: Enterprise Video Platforms and Webcasting, Q1 2015 report at www.sonicfoundry.com/ForresterWave.

About Sonic Foundry®, Inc.

Sonic Foundry (NASDAQ: SOFO) is the trusted global leader for video capture, management and webcasting solutions in education, business and government. The patented Mediasite Enterprise Video Platform transforms communications, training, education and events for more than 3,000 customers in over 60 countries. The company empowers organizations to reach everyone through the power of video; accelerating knowledge-sharing, preserving valuable content, building stronger teams and getting results. Sonic Foundry is the leader in Aragon Research’s Globe for Video Content Management, Frost & Sullivan’s lecture capture leader for seven consecutive years, a leader in Forrester’s Enterprise Video Platforms and Webcasting Wave and a challenger in Gartner’s Magic Quadrant for enterprise video content management.

© 2015 Sonic Foundry, Inc. Product and service names mentioned herein are the trademarks of Sonic Foundry, Inc. or their respective owners.

(SLAB) Advises Bluegiga on Its Sale to Silicon Labs

— M&A transaction in the Internet of Things ecosystem advised by leading global M&A technology advisor, Mooreland Partners

LONDON, Feb. 4, 2015  — Mooreland Partners (http://www.moorelandpartners.com), the leading global technology-focused M&A advisory firm, today announced that it has acted as the sole financial advisor to Bluegiga on its sale to Silicon Labs. The acquisition of Bluegiga, which offers market-leading wireless solutions to a wide variety of Internet of Things (IoT) applications and markets, further strengthens Mooreland’s position among the most active advisors to the electronics and industrial technologies sector.

“The Bluegiga transaction confirms that IoT continues to be a highly strategic area,” said Peter Globokar, Managing Director in Mooreland’s European office.” This is also an important transaction that sees a leading semiconductor vendor invest in the IoT module arena,” added Charlie Bullock, Managing Director in Mooreland’s Silicon Valley office.

Bluegiga provides high-performance short-range wireless modules and integrated software stacks, developing and selling a range of feature-rich Bluetooth, Bluetooth Smart-Ready, Bluetooth Smart and Wi-Fi solutions for short-range connectivity applications across IoT. The Company’s modules and proprietary software stacks combine seamlessly, resulting in easy-to-use products that have been rapidly designed-in and used by over 1,500 customers historic and current worldwide, many of them global tier-1 OEMs. Bluegiga’s products are integrated into a wide range of OEM products in multiple markets including industrial, commercial, consumer, automotive, retail (iBeacon and POS), residential, and health and fitness. Bluegiga was founded in 2000 and is headquartered in Espoo, Finland, with sales offices in China and the U.S.

Silicon Labs (NASDAQ: SLAB) is a leading provider of silicon, software and system solutions for the Internet of Things, Internet infrastructure, industrial automation, consumer and automotive markets. The Company provides customers with significant advantages in performance, energy savings, connectivity and design simplicity. Backed by a world-class engineering teams with strong software and mixed-signal design expertise, Silicon Labs empowers developers with the tools and technologies they need to advance quickly and easily from initial idea to final product. Mooreland Partners is well positioned as an international technology-focused M&A firm to advise on the growing number of cross-border M&A transactions. According to a recent article in the Financial Times, “In the first nine months of 2014, the value of M&A is nearly two-thirds higher than it was in the same period in 2013, at $2.66tn – a level of activity not seen since 2008.”

ABOUT MOORELAND PARTNERS
Founded in 2002, Mooreland Partners is a leading independent investment bank providing M&A and private capital advisory services to the global technology industry, serving clients from its offices in Silicon Valley, Greenwich (CT), and London. Mooreland’s team of almost 50 banking professionals delivers industry domain and transaction expertise across all major technology sectors including communications technology, mobile and digital media, enterprise software and services, as well as industrial technology and electronics. Follow us on Twitter @MoorelandGlobal or learn more at www.moorelandpartners.com.

All trademarks contained herein are the property of their respective owners.